Latest information on COVID-19

ABOUT US

            The Leeper laboratory studies the vascular biology of atherosclerosis and aneurysm disease.  We are interested in the molecular mechanisms that mediate vascular disease, and developing new translational therapies directed against them.  Our group uses a combination of hypothesis-free genetic approaches, favoring the concept that insights generated in this manner are likely to have relevance to human disease.  Currently, our major focus is on a process known as ‘programmed cell removal’, or ‘efferocytosis’ (Latin: to carry the dead to the grave’).  We seek to determine why diseased cells accumulate in the atherosclerotic plaque, and how to harness the power of the immune system as a means to reactivate their removal and stabilize the vulnerable lesion.   Our group pursues the goal of true ‘bench-to-bedside’ translation, bringing together interdisciplinary experts spanning the fields of genomics, molecular biology, translational vascular biology, and clinical Vascular Medicine.  Ultimately, we seek to train the next generation of investigators and physician-scientists who will develop a platform of new therapies directed against atherosclerosis, which is now the leading killer worldwide. 

 


Heart Health

"Good vascular health is the key to longevity"

Watch Elsie Ross, MD Vascular Surgeon and Eri Fukaya, MD Vascular Medicine Specialist, discuss the importance of vascular health and how to protect your vascular system.

News, Events, and Team Milestones

Publication in Nature Nanotechnology

Trojan horse nanoparticles deliver anti-atherosclerotic therapy specifically to the diseased blood vessel

American Society for Clinical Investigation

 Congratulations to Dr. Leeper for being inducted into the American Society for Clinical Investigation (ASCI, “Young Turks”)

2022 Plaqomics Leducq Consortium annual meeting

Great fun in Amsterdam at the 2022 Plaqomics Leducq Consortium annual meeting (with trip to the tulip festival!)

Nature Cardiovascular Research

Congratulations to Kai Jarr for his new manuscript on statin pleiotropy which was featured on the cover of Nature Cardiovascular Research for March 2022!
Link to Article